All Episodes
touchPODCAST — 558 episodes
Empowering choice in HIV care: Moving beyond daily pills to person‐centred ART strategies
Recognizing MOGAD: Defining a distinct demyelinating disease
Systemic mastocytosis: Making the right decisions at the right time (video 3)
Systemic mastocytosis: Making the right decisions at the right time (video 2)
Systemic mastocytosis: Making the right decisions at the right time (video 1)
Immunotherapy in R/M NPC: Interpreting the evidence and individualizing care
Chronic and/or recurrent postoperative intraocular inflammation: Improving diagnosis, classification and management
Advancing the management of HER2-altered NSCLC: Interpreting the latest clinical trial data
Where we are now in PDAC care: Clinical insights, emerging biomarkers and evolving therapeutic strategies
Reimagining Alzheimer’s care: Harnessing subcutaneous therapies and early diagnostic innovation to transform patient lives
Building confidence in geographic atrophy care: From diagnosis to dialogue
Beyond ATTR in Japan: Accurate diagnosis of cardiac AL in the TTR stabilizer era (in Japanese)
Targeting pathogenic mechanisms in gMG: From complement- and FcRn-directed therapies to B- and T-cell-targeted approaches
The art and science of presbyopia-correcting intraocular lens selection: From preoperative planning to patient satisfaction
Unraveling the cortisol connection: Hard-to-control hypertension and hyperglycemia
Reducing attrition and maximizing ADC impact in metastatic breast cancer
The art of diagnosing CIDP: Strengthening diagnostic confidence
The key to ketoacidosis: Unlocking the potential for better DKA monitoring and detection
Optimizing outcomes in advanced endometrial carcinoma: Navigating guidelines, biomarker-driven immunotherapy and irAE management
Personalizing cataract surgery: From pre-operative precision to functional vision outcomes
Cracking the code of CIDP: Mastering diagnostic precision
Looking beyond VEGF to target BRB dysfunction in DME: Novel approaches to prevent vision loss
Unlocking new potential: Rationale and evidence for dual EZH2/AR inhibition in mCRPC
Integrating neurosensory pathway insights into modern dry eye management
Computational pathology in NSCLC: From biomarker discovery to clinical integration
Shaping the future of PDAC care: Scientific advances and therapeutic innovation
Exploring all angles: Neuroprotective strategies beyond IOP in primary and steroid-induced open-angle glaucoma
Optimizing presbyopia-correcting IOL selection and patient expectations
Advancing outcomes in CP-CML: Guideline-directed approaches to treatment decision-making, monitoring and toxicity management
The bare necessities of hyperphagia in Prader–Willi syndrome: Expert insights on recognition and management
Targeting brain metastases in advanced NSCLC: The emerging impact of ADCs
Evolving paradigms in PNH management: Interpreting the latest data
Diagnosis, multidisciplinary monitoring and individualized management in LOPD
Unlocking the possibilities of BCMA-directed therapies in RRMM: Latest perspectives from IMS and ASH 2025
Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC
Evolving strategies in low-grade serous ovarian cancer: Applying the evidence to optimize patient care
Managing cytopenias: The path to transfusion independence for patients with myelofibrosis
Innovations and advances in CML: Focus on navigating early-line options and maintaining quality of life
Breakthroughs in treating NSCLC: Targeting KRAS
HER2 in focus: Advancing treatment for biliary tract and gastroesophageal cancers
Delivering state-of-the-art care for GEP-NETs: Evidence-based strategies for PRRT
Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC
Eyeing better outcomes in diabetic macular oedema: Clinical insights on the evolving role of corticosteroids
Diagnosis and treatment of patients with Lennox–Gastaut syndrome
Updates in hypertrophic cardiomyopathy care: Bridging the current treatment gaps with emerging novel therapies
Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC
Staying ahead of the curve in HNSCC care: Refining the role of immunotherapy across disease stages
FCS unmasked: Closing gaps in diagnosis, treatment and patient support
Achieving effective lifespan care in sickle cell disease: From recognizing the burden to novel therapeutics
Bridging diagnostic and therapeutic gaps in Fabry disease management
Applying patient and disease characteristics to guide R/M NPC treatment
Therapeutic advances in RRMM: What is the latest on practical application of BCMA-directed therapies?
Phacoemulsification in cataract surgery: Evolving options to optimize refractive outcomes
Stargardt disease: Improving awareness, diagnosis and patient support
Mastering DKA management: From pathophysiology to prevention and ketone monitoring strategies
A case-based discussion on PAH: Optimizing early detection, risk stratification and treatment decision-making
Continuous glucose monitoring for cardiovascular risk reduction: The next frontier in preventive care
HER2 as a targetable biomarker in gastrointestinal oncology
Navigating the evolving role of immunotherapy in advanced endometrial carcinoma
Focus on treatment advances for ATTRv: A heterogeneous, highly debilitating and ultimately fatal disease
Navigating the treatment of RRMM with BCMA-directed therapies: Updates from COMy, ASCO and EHA 2025
Advancing care for patients with infantile haemangiomas: Timing is key
Incorporating ADCs into the treatment of mBC: Practical considerations for the community oncologist
Multidisciplinary management of TNBC Integrating immunotherapies for early and metastatic disease
Applying immunotherapy in clinical practice for patients with early-stage NSCLC
Applying immunotherapy in clinical practice for patients with early-stage NSCLC
Towards personalized care for people living with HIV: Supporting open dialogue and informed treatment choices
RET-positive NSCLC: Translating insights into targeted approaches
RET-positive NSCLC: Translating insights into targeted approaches
Advances in dry eye disease: From diagnosis to new treatment targets
Recent advances in the care of patients with geographic atrophy: Bringing new and emerging therapies into focus
The potential of BTKi therapies in delaying MS progression
Reducing burden of disease in gMG: Exploring the role of FcRn inhibitors
MDT perspectives on why and how to implement continuous glucose monitoring in T2D
MDT perspectives on evolving options for insulin therapy
MDT perspectives on understanding clinical inertia in T2D
Navigating the clinical impact of TROP2-targeting in NSCLC
Navigating the clinical impact of TROP2-targeting in NSCLC
Integrating treatment advances for alpha-mannosidosis into effective MDT care - touchNEUROLOGY
Integrating treatment advances for alpha-mannosidosis into effective MDT care - touchENDOCRINOLOGY
The evolving standard of care for advanced/recurrent endometrial cancer: A practice-focused discussion of immunotherapy
Tailoring treatment in myelofibrosis: Addressing anaemia and thrombocytopenia
Video 3: MDT perspectives on identifying and managing key ADC treatment toxicities in patients with metastatic breast cancer
Video 2: MDT perspectives on communicating ADC treatment toxicities to patients with metastatic breast cancer
Video 1: MDT perspectives on the safety profiles of current and emerging ADCs in metastatic breast cancer
Precision in practice: Adopting emerging therapies for retinal diseases to reduce burden of disease
Expanding horizons for patients with Pompe disease: Using data to guide clinical practice
Expanding horizons for patients with Pompe disease: Using data to guide clinical practice
Expanding horizons for patients with Pompe disease: Using data to guide clinical practice
Expanding horizons for patients with Pompe disease Using data to guide clinical practice
MDT perspectives on the importance of patient engagement in PARPi use - Video 3
MDT perspectives on understanding precision medicine to guide PARPi use in mCRPC - Video 2
MDT perspectives on unlocking the data on PARPi to support shared decision-making in mCRPC - Video 1
The next frontier in managing obesity and T2D: The role of novel combinations for touchCARDIO
The next frontier in managing obesity and T2D: The role of novel combinations for touchENDOCRINOLOGY
From clinical trials to clinical practice: Applying CDK4/6 inhibitors in HR+/HER2– early breast cancer
Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals
Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals
Looking to the future in the treatment of steroid-refractory chronic GvHD
Looking to the future in the treatment of steroid-refractory chronic GvHD
Updates in BCMA-directed therapies in multiple myeloma from ASH 2024
Updates in BCMA-directed therapies in multiple myeloma from ASH 2024
RAS mutations and personalized cancer care: Targeting the future
What’s new in primary ITP? Key updates from ASH 2024
What’s new in primary ITP? Key updates from ASH 2024
Focused insights: Data implications of ADCs in NSCLC treatment
Focused insights: Data implications of ADCs in NSCLC treatment
Collaboration in chronic ITP: Improving quality of life and patient outcomes - touchSYMPOSIUM for touchONCOLOGY
Collaboration in chronic ITP: Improving quality of life and patient outcomes - touchSYMPOSIUM for touchHAEMATOLOGY
Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchONCOLOGY
Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchNEUROLOGY
Advancing the treatment of muscle-invasive bladder cancer: Updates on immunotherapy in the perioperative setting
Navigating treatment choices in high-risk early-stage melanoma - touchDERMATOLOGY
Navigating treatment choices in high-risk early-stage melanoma - touchONCOLOGY
Advances in IOL technology and power calculations: Updates and innovations from 2024
Supporting healing in epidermolysis bullosa: Innovations and new directions for care
Primary biliary cholangitis: Appraising the changing therapeutic landscape
Primary biliary cholangitis: Appraising the changing therapeutic landscape
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3
touchMDT for touchRESPIRATORY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?
touchMDT for touchRESPIRATORY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?
touchMDT for touchRESPIRATORY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?
touchMDT for touchONCOLOGY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)?
touchMDT for touchONCOLOGY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)?
touchMDT for touchONCOLOGY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?
Vaccination strategies for pneumococcal disease
Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024
Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024
Pharmacological management of agitation in Alzheimer's dementia
touchIN CONVERSATION - Pulmonary arterial hypertension: A practical roadmap from diagnosis to treatment - touchCARDIO
touchIN CONVERSATION - Pulmonary arterial hypertension: A practical roadmap from diagnosis to treatment - touchRESPIRATORY
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 1
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 2
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 1
touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 2
Targets in early NSCLC: A focus on EGFR-mutant treatment options
Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024
Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024
Innovations in glaucoma care: Targeting pathophysiology to expand treatment options
Experts in dermatology discuss the latest in treating moderate-to-severe atopic dermatitis in children and adolescents
Experts in dermatology discuss the latest in treating moderate-to-severe atopic dermatitis in children and adolescents
Updates in recurrent/metastatic nasopharyngeal carcinoma: The evolving role of immune checkpoint inhibitors
touchMDT – A comprehensive approach to symptom care in PBC – Discussion 3 - touchENDOCRINOLOGY
touchMDT – Symptom assessment and monitoring in clinical practice – Discussion 2 - touchENDOCRINOLOGY
touchMDT – Pruritus in PBC and me: The patient experience – Discussion 1 - touchENDOCRINOLOGY
touchMDT – Pruritus in PBC and me: The patient experience – Discussion 1 - touchDERMATOLOGY
touchMDT – Symptom assessment and monitoring in clinical practice – Discussion 2 - touchDERMATOLOGY
touchMDT – A comprehensive approach to symptom care in PBC – Discussion 3 - touchDERMATOLOGY
touchMDT – A comprehensive approach to symptom care in PBC – Discussion 3 - touchIMMUNOLOGY
touchMDT – Symptom assessment and monitoring in clinical practice – Discussion 2 - touchIMMUNOLOGY
touchMDT – Pruritus in PBC and me: The patient experience – Discussion 1 - touchIMMUNOLOGY
Perspectives on EGFR-mutant and wildtype NSCLC: Tailoring treatment advances in late-stage disease - touchRESPIRATORY
Perspectives on EGFR-mutant and wildtype NSCLC Tailoring treatment advances in late-stage disease - touchONCOLOGY
Expanding HER2 horizons: Implications for NSCLC and beyond
Expanding HER2 horizons: Implications for NSCLC and beyond
Insights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?
Insights from EHA and ISTH 2024: How can we optimize care for patients with chronic ITP?
Continuous glucose monitoring in type 2 diabetes: Overcoming barriers to optimize outcomes
Personalizing care within the MDT for patients with early through to advanced RCC
Selecting ART: Working with people living with HIV to find the best regimen
Thyroid eye disease: An evolving continuum of care
Thyroid eye disease: An evolving continuum of care
Intracranial haemorrhage related to direct oral anticoagulant medications: Latest evidence for reversal strategies
Intracranial haemorrhage related to direct oral anticoagulant medications: Latest evidence for reversal strategies
Expanding the reach of HER2 in solid tumours: A spotlight on tumour-agnostic approaches
The path from detection to personalized long-term care for Fabry disease
The path from detection to personalized long-term care for Fabry disease
The path from detection to personalized long-term care for Fabry disease
Demystifying virology: The link between the HIV life cycle and ART
Knowledge for nurses ADC updates in breast cancer
Maximizing the possibilities in the evolving treatment paradigm for R/R follicular lymphoma
Maximizing the possibilities in the evolving treatment paradigm for R/R follicular lymphoma
Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies
Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies
Early diagnosis and treatment of NMOSD: Practical insights
Early diagnosis and treatment of NMOSD: Practical insights
Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team - Part 1 touchHAEMATOLOGY
Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team - Part 2 touchHAEMATOLOGY
Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team - Part 3 touchHAEMATOLOGY
Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team - Part 4 touchHAEMATOLOGY
Recognizing and managing HLH in the critical care setting Best practice for the multidisciplinary team - Part 1 touchIMMUNOLOGY
Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team - Part 2 touchIMMUNOLOGY
Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team - Part 3 touchIMMUNOLOGY
Recognizing and managing HLH in the critical care setting: Best practice for the multidisciplinary team - Part 4 touchIMMUNOLOGY
Let’s talk about agitation in Alzheimer’s dementia: Prevalence, behavioural symptoms and reaching a diagnosis
Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management
Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management
Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management
Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management
Immunotherapy for early-stage, resectable NSCLC
Immunotherapy for early-stage, resectable NSCLC
Impact of pharmacotherapies for achondroplasia – Discussion 4 / 4
Monitoring and early treatment initiation - Discussion 3
Early recognition of achondroplasia – Discussion 2 / 4
MDT management of achondroplasia – Discussion 1 / 4
Advanced urothelial carcinoma: Expert guidance to navigate an evolving therapeutic landscape
Clinical decision making with immunotherapies in advanced or recurrent endometrial cancer
Optimizing management of bronchiolitis obliterans syndrome: Current strategies, future directions
Optimizing management of bronchiolitis obliterans syndrome: Current strategies, future directions
Gastrointestinal oncology experts discuss precision medicine in the treatment of colorectal cancer
Current treatments and unmet needs in limited-stage small cell lung cancer
Current treatments and unmet needs in limited-stage small cell lung cancer
How to recognize and diagnose agitation in Alzheimer’s dementia – Discussion 5
Understanding agitation in Alzheimer’s dementia – Discussion 4
Managing agitation in Alzheimer’s dementia – Discussion 3
How to recognize and diagnose agitation in Alzheimer’s dementia – Discussion 2
Understanding agitation in Alzheimer’s dementia – Discussion 1
Experts in diabetes discuss the latest developments in basal insulin therapy for type 2 diabetes management
What’s on the horizon to tackle unmet needs in recurrent metastatic SCCHN?
Emerging second-line treatment approaches in advanced NSCLC: The role of ADCs
Expert insights in food allergy: Considerations for diagnosis and management in primary care and beyond
Expert insights in food allergy: Considerations for diagnosis and management in primary care and beyond
Emerging second-line treatment approaches in advanced NSCLC: The role of ADCs
Addressing the diagnosis and management of pet allergies in primary care and beyond
Addressing the diagnosis and management of pet allergies in primary care and beyond
The rationale for protein degradation and immunomodulation in RRMM: Highlighting the latest data and available clinical trials
The rationale for protein degradation and immunomodulation in RRMM: Highlighting the latest data and available clinical trials
Diagnosing and treating patients with EoE: Tackling the difficulties
Diagnosing and treating patients with EoE: Tackling the difficulties
touchMDT – Patient-centric care for prurigo nodularis – Discussion 3
touchMDT – Management of prurigo nodularis – Discussion 2
touchMDT – Burden of prurigo nodularis – Discussion 1
touchMDT – Patient-centric care for prurigo nodularis – Discussion 3
touchMDT – Management of prurigo nodularis – Discussion 2
touchMDT – Burden of prurigo nodularis – Discussion 1
Is HER2 targeting on the horizon for urothelial carcinoma?
Addressing challenges in diagnosis and treatment of IgG4-related gastrointestinal disease
Haemato-oncology experts discuss current considerations and future strategies for CAR T-cell therapies in patients with R/R MCL
Haemato-oncology experts discuss current considerations and future strategies for CAR T-cell therapies in patients with R/R MCL
Overcoming challenges in advanced or metastatic squamous cell lung cancer: Focus on immunotherapy
Overcoming challenges in advanced or metastatic squamous cell lung cancer: Focus on immunotherapy
Haemato-oncology experts discuss managing the practicalities of CAR T-cell therapy in relapsed or refractory follicular lymphoma
Haemato-oncology experts discuss managing the practicalities of CAR T-cell therapy in relapsed or refractory follicular lymphoma
Advances in IOL technology and power calculations: Updates and innovations
Guideline-based treatment of recurrent/metastatic cervical cancer
IgG4-related disease: How to identify, diagnose and treat
Paediatric atopic dermatitis: Evolving strategies for improved management
Paediatric atopic dermatitis: Evolving strategies for improved management
Optimizing the management of patients with relapsing forms of MS: An update on emerging treatment options
Cataract surgery and ocular comorbidities: Key considerations for intraocular lens choice
PSMA-targeted radiopharmaceuticals: An evolving approach to prostate cancer management
Clinical care pathway for Alzheimer’s disease Driving improvements in diagnosis
Using anti-CGRP antibodies for migraine prevention: Key learnings
Treatment of endometrial cancer: Highlights from ESGO 2023
Practical considerations for personalized medicine in thyroid cancer: Which therapies are suited to particular patient profiles?
Practical considerations for personalized medicine in thyroid cancer: Which therapies are suited to particular patient profiles?
Personalized therapy for NSCLC: Biomarker testing, treatment and management in the presence of MET alterations
Personalized therapy for NSCLC: Biomarker testing, treatment and management in the presence of MET alterations
COVID-19 vaccination: What have we learned and what more can we do to address vaccine inequity in the Middle East?
COVID-19 vaccination: What have we learned and what more can we do to address vaccine inequity in Africa?
The mRNA vaccine platform: A novel tool for the rapid development of vaccines against respiratory viral infections
The mRNA vaccine platform: A novel tool for the rapid development of vaccines against respiratory viral infections
Optimizing androgen deprivation therapy (ADT) in advanced prostate cancer
Optimizing IOL selection Focus on IOL calculations in “difficult” eyes
Anti-CGRP antibody preventive treatment of migraine: Practical management
The complement system in NMOSD and MG: A target for therapeutic benefit?
The complement system in NMOSD and MG: A target for therapeutic benefit?
The complement system in NMOSD and MG: A target for therapeutic benefit
Contemporary insights on sickle cell disease complications and recent advances in therapy
Contemporary insights on sickle cell disease complications and recent advances in therapy
Contemporary insights on sickle cell disease complications and recent advances in therapy
Contemporary insights on sickle cell disease complications and recent advances in therapy
New and emerging agents in HER2-negative metastatic breast cancer Implications for current and future practice
DOACs and reversal agents for patients experiencing ICH: Latest evidence - touchCARDIOLOGY
DOACs and reversal agents for patients experiencing ICH: Latest evidence - touchNEUROLOGY
Key considerations in the management of irAEs with ICIs in advanced or recurrent endometrial cancer
Importance of shared decision making in the management of endometrial cancer
Improving outcomes with ICIs in advanced or recurrent endometrial cancer
Optimizing outcomes of JAK inhibition in myelofibrosis: Practical considerations for the clinic - touchHAEMATOLOGY
Optimizing outcomes of JAK inhibition in myelofibrosis: Practical considerations for the clinic - touchONCOLOGY
Preventing HPV-associated cancer by maximizing vaccine uptake
Preventing HPV-associated cancer by maximizing vaccine uptake
Fulfilling the potential of HER2-targeting in colorectal cancer
Migraine prevention in the real world: Exploring the role of anti-CGRP antibodies - Modules 1 & 2
Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
Current and future considerations for the use of immune checkpoint inhibitors in NSCLC
Current and future considerations for the use of immune checkpoint inhibitors in NSCLC
Shaping ART around individual needs: Maximizing adherence and quality of life
Latest developments in neuromyelitis optica spectrum disorder (NMOSD): Diagnostics, treatments and patient-centered care
Latest developments in neuromyelitis optica spectrum disorder (NMOSD): Diagnostics, treatments and patient-centered care
Key considerations for treatment selection and sequencing in patients with RRMM: Lessons from real-life clinical practice
Key considerations for treatment selection and sequencing in patients with RRMM Lessons from real-life clinical practice
Individualizing long-term treatment and care in active MS
MDT perspectives on approaches for the use of immune checkpoint inhibitor therapy in patients with solid tumours
MDT perspectives on the role of biomarkers in informing immune checkpoint inhibitor use across tumour types
MDT perspectives on strategies for identifying and monitoring immune-related adverse events
MDT perspectives on indications for immune checkpoint inhibitors in patients with solid tumours
Adverse event identification and management in locally advanced/metastatic urothelial carcinoma
Experts in infectious diseases discuss the practical considerations for COVID-19 vaccination in the Middle East
Part 1 - Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
Part 1 - Advancing the management of adult solid tumours in 2023, and beyond: Unlocking the potential of radiopharmaceuticals
Experts in infectious diseases discuss the practical considerations for COVID-19 vaccination in Africa
Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management
Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management
Clinical updates from SGO 2023 on PARP inhibitors in ovarian cancer
Improving outcomes in pulmonary arterial hypertension: A multidisciplinary approach
Improving outcomes in pulmonary arterial hypertension: A multidisciplinary approach
ICI-based combinations for advanced/metastatic renal cell carcinoma: Highlights from ASCO GU 2023
Blood-based biomarkers: Supporting the diagnosis and treatment of Alzheimer’s disease
Reducing transmission of COVID-19 Spotlight on vaccines
Personalized treatment of advanced HER2-negative gastric or gastroesophageal junction cancer: Current status and future perspectives
Optimizing strategies for the treatment of colorectal cancer in the biomarker era - Modules 1 & 2
Improving outcomes of immune-related adverse events: The crucial role of the pharmacist
Optimizing patient outcomes in Cushing’s disease
Treatment pathways with a focus on medical therapies for Cushing’s disease
Managing Cushing’s disease and goals of medical therapy
Optimizing strategies for the treatment of colorectal cancer in the biomarker era - Module 1
MDT perspectives on novel approaches to overcome resistance with standard-of-care immunotherapy for non-driver mutation metastatic NSCLC
MDT perspectives on tracking prognostic and predictive biomarkers for immunotherapy
MDT and patient perspectives on shared decision making for emerging treatment options
MDT perspectives on the limitations of standard of care immunotherapy for non-driver mutation metastatic NSCLC
Navigating pyruvate kinase deficiency today: How can the disease burden and unmet treatment needs be addressed?
Key considerations for the clinical management of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)
Navigating pyruvate kinase deficiency today: How can the disease burden and unmet treatment needs be addressed?
MDT and patient advocate perspectives on the key signs and symptoms of DMD
MDT and patient advocate perspectives on diagnosing DMD and how to screen
MDT perspectives on established methods for managing DMD
MDT perspectives on novel pharmacological and gene therapies for patients with DMD
Understanding the pathophysiology of multiple sclerosis and the development of new therapies
Understanding the pathophysiology of multiple sclerosis and the development of new therapies
Emerging data with immunotherapy in ESCC and potential impact for clinical practice
Improving the alpha-mannosidosis patient journey
Improving the alpha-mannosidosis patient journey
Improving the alpha-mannosidosis patient journey
HER2 testing in colorectal cancer
Managing treatment side effects in HER2-positive colorectal cancer
Supporting patients with HER2-positive colorectal cancer
Utilizing HER2-targeted treatments in colorectal cancer
Navigating the complexities of the NSCLC treatment pathway: A focus on antibody-drug conjugates
Higher-risk MDS: An update on emerging novel agents
Supporting families to optimize outcomes
Supporting families to optimize outcomes
The role of the MDT in managing paediatric severe type 2 asthma
The role of the MDT in managing paediatric severe type 2 asthma
The use of biologics in children with severe type 2 asthma
The use of biologics in children with severe type 2 asthma
Accurately diagnosing severe type 2 asthma in children
Accurately diagnosing severe type 2 asthma in children
MDT perspectives on the current and emerging second-line treatment options for SCLC
MDT perspectives on managing side effects associated with second-line treatment for SCLC
MDT perspectives on tailoring second-line treatment selection to each patient with relapsed SCLC
MDT perspectives on managing side effects associated with second-line treatment for SCLC
MDT perspectives on tailoring second-line treatment selection to each patient with relapsed SCLC
MDT perspectives on the current and emerging second-line treatment options for SCLC
A patient’s perspective: Best practice for shared decision making in the prevention and treatment of migraine
Optimizing outcomes for patients with Alzheimer’s disease: A focus on transdermal therapy
What are the implications of the latest data for HER2-targeted therapies in HER2-tested patients with colorectal cancer?
Improving outcomes in severe paediatric asthma: Insights from a specialist and a PCP
Improving outcomes in severe paediatric asthma: Insights from a specialist and a PCP
Tackling unmet needs in chronic myeloid leukemia What’s next in the treatment algorithm
MDT perspectives on preventing or delaying TSC-associated seizures
MDT and patient caregiver perspectives on emerging agents for TSC-associated seizures
MDT and patient caregiver perspectives on the treatment options for TSC-associated seizures
Prurigo nodularis: Improving awareness, diagnosis, management and quality of life
Achieving best practice management of primary biliary cholangitis now and in the future
Achieving best practice management of primary biliary cholangitis now and in the future
Scanning the horizon of pharmacological treatments for women experiencing vasomotor symptoms during menopause What’s new in 2022
PARP inhibitors as first-line maintenance therapy in ovarian cancer: How can data from ESGO 2022 guide clinical practice?
Experts in NTM-LD discuss optimizing the management of patients with NTM-LD to improve outcomes
Experts in NTM-LD discuss optimizing the management of patients with NTM-LD to improve outcomes
MDT and patient perspectives on the MDT’s role in stroke management
MDT perspectives on guidelines for stroke prevention in T2D
MDT and patient perspectives on risk factors for stroke in T2D
MDT and patient perspectives on the MDT’s role in stroke management
MDT perspectives on guidelines for stroke prevention in T2D
MDT and patient perspectives on risk factors for stroke in T2D
MDT perspectives on how GLP-1 RAs can reduce stroke risk
MDT perspectives on how GLP-1 RAs can reduce stroke risk
Immunogenicity of immune checkpoint inhibitors: Implications for clinical practice
MDT perspectives on managing patients with complement inhibitors
MDT and patient perspectives on recognizing and referring patients with PNH
MDT and patient perspectives on the patient journey in PNH
Selecting the optimal treatment for patients with chronic myeloid leukaemia after two prior lines of therapy
MDT and patient perspectives on the diagnostic tools for non-CF bronchiectasis
MDT and patient perspectives on the clinical presentation of non-CF bronchiectasis
MDT perspectives on the pathophysiology and comorbidities of non-CF bronchiectasis
MDT and patient perspectives on the clinical presentation of non-CF bronchiectasis touchRESPIRATORY
MDT perspectives on the pathophysiology and comorbidities of non-CF bronchiectasis touchRESPIRATORY
MDT and patient perspectives on the diagnostic tools for non-CF bronchiectasis
Experts discuss latest guidelines and how novel treatments can reduce ASCVD risk in patients with dyslipidemias
Experts in endocrinology and in primary care discuss addressing cardiorenal outcomes in CKD and T2D
Experts in endocrinology and in primary care discuss addressing cardiorenal outcomes in CKD and T2D
Getting personal: Individualizing therapy for cold agglutinin disease
Understanding the immunopathogenesis of CAD: What are the implications of new and emerging therapies?
Understanding the immunopathogenesis of CAD: What are the implications of new and emerging therapies?
Advances in immunotherapies and targeted treatments for patients with bladder cancer: An update from ESMO 2022
Considering the needs and preferences of patients at each treatment decision-making moment
Imaging disease progression in MS
Managing MS in patients over their lifetime
Navigating the evolving treatment landscape in mTNBC: What are the key considerations for clinical practice today?
Managing disease progression: Considerations for treatment selection and sequencing
Supporting treatment adherence: What strategies are needed for safety management?
Mapping an individualized treatment plan: What role does the MDT play?
Achieving a timely and accurate diagnosis: How can multidisciplinary input address current challenges?
Managing disease progression: Considerations for treatment selection and sequencing
Supporting treatment adherence: What strategies are needed for safety management?
Mapping an individualized treatment plan: What role does the MDT play?
Achieving a timely and accurate diagnosis: How can multidisciplinary input address current challenges?
Managing disease progression: Considerations for treatment selection and sequencing
Supporting treatment adherence: What strategies are needed for safety management?
Mapping an individualized treatment plan: What role does the MDT play?
Achieving a timely and accurate diagnosis: How can multidisciplinary input address current challenges?
Understanding alopecia areata: Current perspectives and emerging therapies for a complex disease
Advancing the management of MDS and AML: Novel immune-based approaches
Experts in cytomegalovirus in solid organ transplants discuss management strategies and emerging therapeutic options
Experts in cytomegalovirus in solid organ transplants discuss management strategies and emerging therapeutic options
What’s new for eosinophilic esophagitis? A case-based discussion of patient care
What’s new for eosinophilic esophagitis? A case-based discussion of patient care
Higher-risk MDS and newly diagnosed AML What are the latest developments from EHA 2022
Advances in the first-line treatment of ES-SCLC: From clinical data to daily practice
Investigating KRAS-G12C inhibitors: How might they improve outcomes for patients with solid tumours?
Improving outcomes for patients with advanced renal cell carcinoma
Experts in paediatric endocrinology discuss the assessment and treatment of children with achondroplasia
Investigating KRAS-G12C inhibitors: How might they improve outcomes for patients with solid tumours?
Current and emerging treatments for chronic myeloid leukaemia: What have we learnt from the EHA Hybrid Conference 2022?
Maximizing the potential of PARP inhibitors as first-line maintenance therapy in ovarian cancer
The practicalities of eosinophilic oesophagitis management: A closer look at emerging biologic treatment options
The practicalities of eosinophilic oesophagitis management: A closer look at emerging biologic treatment options
Treatment sequencing and the benefits of DMTs
Breast cancer specialists discuss risk stratification and novel treatment strategies in high-risk HR+ HER2– early breast cancer
How can real-world evidence guide the management of elderly and frail patients with multiple myeloma?
Navigating the challenges of treatment provision in recurrent/metastatic HNSCC
Managing EoE: What options are emerging for patients? - Conversation 3
Symptoms of EoE: What is the burden for patients? - Conversation 2
Pathophysiology of EoE: What do we see in patients? - Conversation 1
Managing EoE: What options are emerging for patients? - Conversation 3
Symptoms of EoE: What is the burden for patients? Conversation 2
Pathophysiology of EoE What do we see in patients - Conversation 1
Experts discuss current and future best practice for the management of non-cystic fibrosis bronchiectasis
Experts discuss current and future best practice for the management of non-cystic fibrosis bronchiectasis
MDT and patient advocate perspectives on what can be learned from patients with CML
MDT perspectives on maximizing quality of life for patients with CML
MDT perspectives on minimizing TKI-associated toxicities in patients with CML
MDT perspectives on later-line treatment options for CML
Extending the benefit of PARP inhibitors through combinations for advanced prostate cancer - Conversation 3
PARP inhibitor combination clinical trials for advanced prostate cancer - Conversation 2
Rationale for PARP inhibitor combinations for advanced prostate cancer - Conversation 1
ENT experts discuss minimizing the clinical burden of chronic rhinosinusitis with nasal polyposis
ENT experts discuss minimizing the clinical burden of chronic rhinosinusitis with nasal polyposis
Considerations for the selection of disease-modifying treatments in SMA: A case-based discussion
Improving patient outcomes in relapsing MS: Current oral DMTs and emerging therapies
PARP inhibitors as first-line maintenance therapy in ovarian cancer: Update from SGO 2022
MDT and patient perspectives on the role of GLP-1 RAs in the T2D management pathway
MDT and patient perspectives on the safety of GLP-1 RAs and managing their side effects
MDT discussions on the rationale for using GLP-1 as a therapeutic target in T2D
Improving patient outcomes in moderate-to-severe ulcerative colitis
AAAAI 2022: Improving outcomes for patients with eosinophilic esophagitis
AAAAI 2022: Improving outcomes for patients with eosinophilic esophagitis
Unlocking CSU pathogenesis to shape the future treatment landscape
Identifying, diagnosing and treating patients with later-onset SMA
Identifying, diagnosing and treating patients with later-onset SMA
The relationship between people living with HIV and their multidisciplinary team for optimal adherence to ART
Long-term ART adherence, comorbidities and quality of life for people living with HIV
Assessing readiness to initiate ART to maximize adherence
Overcoming barriers to PrEP to optimize uptake and adherence
Sharing data to improve outcomes in LACC: What’s on the horizon?
MDT: Optimizing the patient journey in LACC: Can we reduce the burden?
MDT: Current treatment of LACC: Where are we now?
MDT and patient perspectives on overcoming the challenges of implementing SDM in EBC
MDT perspectives on evidence for the effects of SDM on patient outcomes in EBC
MDT and patient perspectives on essential elements of successful SDM in EBC
MDT: Sharing data to improve outcomes in LACC: What’s on the horizon?
Considering the complete picture in neuromyelitis optica spectrum disorder
Considering the complete picture in neuromyelitis optica spectrum disorder
MDT perspectives on the latest guideline recommendations for the treatment of HFrEF
MDT and patient perspectives on new and emerging therapies for HFrEF
MDT and patient perspectives on the importance of the MDT in HF management
Multidisciplinary care for CSCC
CSCC treatment: Systemic therapy
CSCC treatment: Surgery or radiotherapy
Diagnostic workup in CSCC
Multidisciplinary care for CSCC
CSCC treatment: Systemic therapy
CSCC treatment: Surgery or radiotherapy
Diagnostic workup in CSCC
Multidisciplinary care and quality of life of adolescents/adults with SMA
Support structures for adolescents with SMA transitioning to the adult healthcare system
Later-onset SMA: Presentation and differential diagnosis
Multidisciplinary care and quality of life of adolescents/adults with SMA
Support structures for adolescents with SMA transitioning to the adult healthcare system
Later-onset SMA: Presentation and differential diagnosis
Personalized treatment of RET-altered thyroid cancers
Personalized treatment of RET-altered thyroid cancers
Focus on cognitive impairment in the diagnosis and management of relapsing MS – Part 3
Focus on cognitive impairment in the diagnosis and management of relapsing MS - Part 2
Focus on cognitive impairment in the diagnosis and management of relapsing MS - Part 1
MDT and patient perspectives on the importance of treatment intensification, weight loss, and education in T2D and obesity
MDT and patient perspectives on GLP-1 RA therapy and emerging incretin-based dual agonists in T2D and obesity
MDT perspectives on the role of incretin hormones in wellness and in T2D
Targeting the pathobiology of ESCC: Potential impact of immunotherapy on clinical practice
The evolving role of antibody–drug conjugates in the treatment of urothelial carcinoma
MDT and patient perspectives on the long-term management of patients with severe type 2 asthma
MDT and patient perspectives on the disease burden of severe asthma
MDT perspectives on biologic treatment selection in severe type 2 asthm
MDT and patient perspectives on the disease burden of severe asthma
MDT perspectives on biologic treatment selection in severe type 2 asthma
Advancing the treatment of MDS and AML: An update from ASH 2021
Immunotherapy for recurrent or metastatic head and neck squamous cell carcinoma
HPV infection and TGF-β: Translating the science into treatments for HPV-associated cancers
MDT and patient perspectives on the long-term management of patients with severe type 2 asthma
Immune checkpoint inhibitors in prostate cancer: Current and future practice
Targeting the pathobiology of ESCC: Potential impact of immunotherapy on clinical practice
Experts discuss how endotyping and biomarkers can help to guide treatment selection in severe type 2 asthma - touchIMMUNOLOGY
Experts discuss how endotyping and biomarkers can help to guide treatment selection in severe type 2 asthma - touchRESPIRATORY
Improving outcomes for patients with NTM-LD
Improving outcomes for patients with NTM-LD
Achieving sustained outcomes for moderate-to-severe atopic dermatitis
Perspectives on the latest clinical data for targeted therapies for thyroid cancer
Perspectives on biomarker testing and its influence on outcomes in patients with thyroid cancer
An overview of thyroid cancers from a MDT of experts
Expert opinions on the management of EDS due to OSA or narcolepsy
Expert opinions on the management of EDS due to OSA or narcolepsy
Evolving Standards Of Patient Care in Hepatocellular carcinoma 3
Evolving Standards Of Patient Care in Hepatocellular carcinoma 2
Evolving Standards Of Patient Care in Hepatocellular carcinoma
Choosing IOLs for patients with cataracts: Insights from an expert
Experts discuss the latest data for emerging HER2-directed therapies in advanced breast cancer
Making the case for the MDT in NSCLC
The role of biomarker testing in NSCLC
Navigating treatment decisions in NSCLC
Initial assessment of NSCLC
Experts discuss the emerging role of SERDs in HR+ breast cancer
Novel targeted therapies for NSCLC: Exploring HER2 dysregulation
Experts discuss non-steroidal MRAs for the treatment of patients with T2D and CKD
Immunotherapy and evolving approaches for basal cell carcinoma
MDT and patient perspectives on real-world use of antihyperglycemic therapies to manage T2D and obesity
MDT and patient perspectives on antihyperglycemic therapies and their association with weight loss
Perspectives on the mechanism linking obesity with T2D
Frontline IO for advanced NSCLC: Updates from ASCO and ESMO 2021
Frontline IO for advanced NSCLC: Updates from ASCO and ESMO 2021
Type 2 diabetes experts discuss achieving individualized glycemic targets in patients with T2D
Investigating immunotherapies for endometrial cancer: Working as a MDT to identify patients and improve outcomes - Part 3
Investigating immunotherapies for endometrial cancer: Working as a MDT to identify patients and improve outcomes - Part 2
Investigating immunotherapies for endometrial cancer: Working as a MDT to identify patients and improve outcomes - Part 1
Immunotherapy and evolving approaches for basal cell carcinoma
Immunotherapy and evolving approaches for basal cell carcinoma
What is the long-term picture for patients with EGFR-mutant NSCLC?
What are the implications of adjuvant therapy data on biomarker evaluation?
How is the advent of adjuvant therapy in NSCLC changing our approach to surgery?
Patient education, evidence-based treatment and biomarkers in HFrEF
Highlights from EHA2021 Virtual 2021: Focus on MDS and AML
Perspectives on the latest data for novel lipid-lowering therapies
Perspectives on how novel lipid-lowering therapies may help address current unmet needs
Perspectives on the risk factors for ASCVD and guidelines for dyslipidaemia management
Perspectives on the latest data for novel lipid-lowering therapies
Perspectives on how novel lipid-lowering therapies may help address current unmet needs
Perspectives on the risk factors for ASCVD and guidelines for dyslipidaemia management
HR+/HER2- advanced breast cancer: How do the latest data on CDK4/6 inhibitors inform clinical decision-making?
Paving the way for optimal disease control in moderate-to-severe type 2 asthma
Paving the way for optimal disease control in moderate-to-severe type 2 asthma
ACR 2020 – Predictors of Response in Nr‑axSpA Treated with Certolizumab Pegol: The C-axSpAnd Study
MAb biosimilars for solid tumours: Perspectives for pharmacists
Highlights from SABCS 2020 Virtual
Highlights from ESMO 2020 Virtual